<DOC>
	<DOCNO>NCT02793154</DOCNO>
	<brief_summary>The primary objective study compare effect albiglutide exenatide gastric myoelectrical activity ( GMA ) , gastric emptying ( GE ) nausea ( measure visual analogue scale [ VAS ] ) subject type 2 diabetes mellitus ( T2DM ) . The study divide two part . Part A characterize GMA , GE nausea response exenatide confirm exenatide positive control Part B . Part B compare effect albiglutide exenatide GMA , GE nausea . Part A single arm , open-label design subject receive 10 microgram ( mcg ) subcutaneous exenatide twice daily 5 day . This part comprise 3 study period : 3-week screening/wash-out , 5-day treatment , follow-up ( within 7 day last dose exenatide ) . The total duration subject 's participation Part A approximately 5 week . Once Part A complete , data review decision progress Part B make . In Part B , subject randomize 1:1 receive either albiglutide ( start dose 30 milligram [ mg ] weekly 4 week , follow 50 mg weekly 4 week ) exenatide ( start dose 5 mcg twice daily 4 week , follow 10 mcg twice daily 4 week ) . The total duration subject 's participation study approximately 15 week .</brief_summary>
	<brief_title>An Exploratory Study Effects Repeat Doses Albiglutide Compared Exenatide Gastric Myoelectrical Activity Gastric Emptying Type 2 Diabetes Mellitus Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Male female , age 18 60 year age time sign informed consent . Type 2 diabetes mellitus diagnose least 6 month prior screen . Subjects treat diet exercise alone stable dose single oral antihyperglycemic medication ( OAM ) metformin , sulfonylurea ( except chlorpropamide ) , sodium glucose cotransporter 2inhibitor , meglitinide least 2 month prior screen Glycated hemoglobin A1C ( HbA1c ) &gt; 6.5 % &lt; =9.0 % screening . If first HbA1c value meet eligibility criterion , HbA1c may rechecked screening . If average determination meet criterion , subject eligible . Fasting plasma glucose ( FPG ) &lt; =210 mg/deciliter ( dL ; central lab ) screening . If first FPG value meet eligibility criterion , FPG may rechecked screen . Patient assessment upper GI symptom severity index screening : Overall score &lt; =20 ( score &gt; =21 &lt; =25 , subject reevaluate 2 week later ) Total score item 19 &lt; =9 Score single item &lt; =2 Body mass index ( BMI ) &gt; 20 kilogram ( kg ) /meter ( ) ^2 &lt; 35 kg/m^2 stable weight ( 5 % report change within 3 month prior screen ) . A female subject eligible participate pregnant ( confirm negative serum human chorionic gonadotrophin [ hCG ] test female reproductive potential [ FRP ] ) , breastfeed , least one follow condition applies : Reproductive potential agrees follow one option list Modified List Highly Effective Methods Avoiding Pregnancy FRP ( eg. , combine oral contraceptive pill ) 30 day prior first dose study medication last dose study medication completion followup visit . Nonreproductive potential define either : Premenopausal one following : document tubal ligation ; document hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion ; hysterectomy ; document bilateral oophorectomy , ; Postmenopausal define 12 month spontaneous amenorrhea age appropriate ( i.e. , &gt; 50 year ) . In questionable case , blood sample simultaneous follicle stimulate hormone &gt; 40 milliInternational units/milliliters ( mL ) estradiol &lt; 40 picograms/mL ( &lt; 140 picomoles/L ) confirmatory , depend local laboratory range . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment For regular use medication ( include protocol excluded medication ) , subject must stable dose least 4 week screen Capable give sign informed consent ; include compliance requirement restriction list consent form protocol Type 1 diabetes mellitus Type 2 diabetes mellitus treat one OAM chronic use insulin within 3 month prior screen Hemoglobin &lt; 11 gram ( g ) /dL ( &lt; 110 g/L ) male subject &lt; 10 g/dL ( &lt; 100 g/L ) female subject screen Fasting triglyceride level &gt; 500 mg/dL screen Hemoglobinopathy may affect proper interpretation HbA1c History cancer full remission least 3 year screen . ( A history squamous cell basal cell carcinoma skin treat cervical intraepithelial neoplasia I II allow ) . Personal family history medullary thyroid carcinoma multiple endocrine neoplasia type 2 History acute chronic pancreatitis . History current severe lactose intolerance History thyroid dysfunction abnormal ( i.e. , outside normal reference range ) thyroid function test assess thyroid stimulate hormone screening . Alanine aminotransferase ( ALT ) &gt; 2.5x upper limit normal ( ULN ) . Bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current active liver biliary disease ( exception Gilbert 's syndrome asymptomatic gallstone otherwise stable chronic liver disease per investigator assessment ) . Clinical diagnosis gastroparesis . History significant GI medical condition chronic esophagitis , peptic ulcer disease , celiac disease , inflammatory bowel disease , unexplained abdominal pain irritable bowel syndrome and/or history surgery opinion investigator likely significantly affect upper GI pancreatic function ( e.g. , gastric bypass , gastric banding , antrectomy , Roux en Y bypass , gastric vagotomy , small bowel resection , surgery think significantly affect upper GI function ) . History hypoglycemia unawareness ( i.e. , absence autonomic warning symptom development neuroglycopenic symptom blur vision , difficulty speaking , feel faint , difficulty thinking , confusion ) . Diabetic complication ( e.g. , active proliferative retinopathy severe diabetic neuropathy ) clinically significant abnormality ( include psychiatric disorder ) , opinion investigator , may pose additional risk administer investigational product may influence data interpretation . Clinically significant cardiovascular and/or cerebrovascular disease time , prior myocardial infarction , unstable angina , stroke , transient ischemic attack document heart failure , screen . Estimated glomerular filtration rate ( eGFR ) &lt; =75 mL/min/1.73 m^2 ( calculate use MDRD formula ) screening . Lung diseases associate pulmonary dysfunction ( e.g . chronic obstructive pulmonary disease ) . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study excluded unless investigator ( consultation Medical Monitor , necessary ) decide document find unlikely introduce additional risk factor interfere study procedure ability interpret study result Unable refrain medication might modify GMA GI motility , prokinetics ( e.g. , erythromycin ) , antiemetic ( e.g. , metoclopromide ) , narcotic ( e.g. , morphine ) , anticholinergic ( e.g. , domperidone ) , antiacid ( e.g. , proton pump inhibitor , H2 blocker ) laxatives , receive within 7 day prior screen high likelihood requirement study . Use oral systemically injected glucocorticoid within 3 month prior randomization high likelihood requirement prolong treatment ( &gt; 1 week ) 4months follow randomization . However , short course oral steroid ( single dose multiple dose 7 day ) may permit provided case discuss Medical Monitor . Inhaled , intraarticular , epidural , topical corticosteroid allow Known allergy albiglutide , exenatide product component ( include yeast human albumin ) , glucagonlike receptor 1 analogue , study treatment excipients OR contraindication ( per principal investigator ) use potential study treatment . Intolerance allergy component GE test meal Received glucagonlike peptide 1 receptor agonist time Receipt investigational drug within 30 day 5 halflives , whichever longer , screen , history receipt investigational antidiabetic drug within 3 month randomization . Exposure 4 investigational medicinal product within 12 month prior first dose day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>gastric empty</keyword>
	<keyword>albiglutide</keyword>
	<keyword>GMA</keyword>
	<keyword>exenatide</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
</DOC>